ZEISS supports the transition of spatial biology to clinical research
- Comprehensive solution portfolio – from multiplex immunofluorescence (mIF) staining reagents to spatial image analyses – designed to meet the challenges of clinical research
- Highly controlled and fully automated operation from slide to report, with optional Laboratory Information Management System (LIMS) integration
- Exceptional speed, high throughput, and reproducible results support drug development as well as translational and clinical biomarker research
Today marks the global launch of ZEISS Axioscan 7 spatial biology. The newly optimized slide scanner is the central component of a novel analytical workflow solution portfolio – spanning from sample staining to result reports – tailored to spatial biology applications in clinical research environments.
Spatial biology describes a highly active area of research which enables in-depth characterization of cellular interactions in their native tissue environment and has significantly fueled our understanding of various diseases and areas of therapy, especially in immuno-oncology. With the transition of this highly promising technology from basic research towards routine clinical application, the demands have significantly increased. Scientists in contract research organizations (CROs), the pharmaceutical industry, biotechnology as well as other related high-throughput laboratories are now facing new challenges when applying spatial biology to support drug development in biomarker discovery, translational research, and clinical trial monitoring. Existing methods are complicated, difficult to scale, and oftentimes do not provide data of sufficient quality or reproducibility to support their work.
'ZEISS has long-standing expertise in providing robust and high-quality solutions for demanding research environments,' says Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. 'We are now providing an end-to-end workflow to bring this quality to high-throughput applications. Automation, standardization, ease-of-use, and seamless integration of AI-powered image analysis enable spatial biology at scale.'
Automated scanning of up to 100 slides in a single run
ZEISS Axioscan 7 spatial biology is newly optimized for multiplex immunofluorescence (mIF) imaging across large cohorts of samples. It allows up to eight fluorescence-stained biomarkers to be studied at the same time and can fully automatically scan up to 100 samples in a single run, significantly enhancing research throughput. A carefully coordinated selection of hardware and software solutions contributes to superior reproducibility of the images and data for longitudinal and multi-site studies.
mIF staining reagents
The OmniVUE™ reagents from our partner Ultivue leverage advanced DNA-based amplification technology designed for high specificity and dynamic range, which can be optimally recorded with the ZEISS Axioscan 7 spatial biology. Ultivue offers ready-to-use validated assays paired with co-optimized analysis algorithms, eliminating the need for assay development and providing instructive data as much as three times faster than competing technologies. The improved instrument and workflow are fully compatible with a broad range of assays, including various mIF reagents, standard IHC, and H&E. Samples stained with different assays can easily be imaged automatically in the same batch.
Fully automated image analysis
The integrated solution by our partner Mindpeak makes image analyses for mIF samples as straightforward as for scoring of standard immunohistochemistry (IHC). Mindpeak's leading technology for clinical-grade IHC image analysis and their streamlined cloud platform now enable the efficient analysis of IHC and mIF-stained tissue images generated by ZEISS Axioscan 7 spatial biology. Spatial biology assays can be paired with pre-optimized analytics that are automatically run after image acquisition, enabling efficient review processes and significantly accelerating the time to results.
Services for advanced lab automation
The new spatial biology workflow improves consistency and operational efficiency through an intuitive workflow manager software. Customization services are available to adapt the workflow to individual laboratory processes and to support integration with Laboratory Information Management Systems (LIMS).
AI-powered scanning and image analysis routines can be fully automated, documented, and controlled to meet lab-specific requirements, reducing the need for manual steps and supporting increased productivity and reproducibility. This enables spatial biology assays to be implemented as part of routine applications, even at high volumes ranging from hundreds to thousands of samples per day.
The solution is available both as a standalone offering and as an upgrade for existing ZEISS Axioscan 7 systems, providing flexible options for implementation and enhanced operational efficiency.
For more information, click here.
Press contact
ZEISS Research Microscopy Solutions
Vybhav Sinha
Phone: +49 3641 64 3949
Email: [email protected]
www.zeiss.com/newsroom
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous
fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena,
the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
ZEISS Research Microscopy Solutions
ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.
Further information at www.zeiss.com/microscopy
Attachments
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 hours ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
Business Upturn
6 hours ago
- Business Upturn
ThreatLocker Chosen for 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Orlando, Florida, Aug. 12, 2025 (GLOBE NEWSWIRE) — ThreatLocker® Chosen for the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies ORLANDO, Fla., Aug. 12, 2025 – ThreatLocker® today announced its inclusion on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. In addition to ranking in the top 8% on the national list, ThreatLocker is No. 7 in the Orlando metro area, No. 47 in the state of Florida and No. 10 in the security industry in the U.S. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment: its independent, entrepreneurial businesses. 'Earning a spot on the Inc. 5000 underscores how central Zero Trust has become in cybersecurity,' said ThreatLocker CEO and Co-founder Danny Jenkins. 'Our proactive approach is essential in an era where cyberattacks are more frequent, more sophisticated, and more disruptive than ever. That's why we're growing so quickly.' This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. For the full list, company profiles, and a searchable database by industry and location, visit: 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' said Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' Since its founding in 2017, ThreatLocker has grown from launching its first product, Allowlisting, to a global cybersecurity leader serving more than 50,000 organizations. Milestones include the introduction of key solutions such as Ringfencing™, Storage Control, Elevation Control, Network Control, Detect, and Cyber Hero® MDR. In 2025, ThreatLocker launched five new solutions: Web Control, Patch Management, Insights, User Store, and Cloud Control. The company also released Defense Against Configurations (DAC) and is now listed on the FedRAMP Marketplace. ThreatLocker has expanded its presence to more than 10 countries, added data centers worldwide, and grown its team to over 600 members, all while continually advancing its Zero Trust endpoint protection platform. Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About ThreatLocker ThreatLocker® is a global cybersecurity leader that helps organizations stop cyberattacks at the source by taking a true Zero Trust approach to securing endpoints. Through powerful tools like Application Allowlisting, Ringfencing™, and Network Control, ThreatLocker gives IT teams the granular control they need to block ransomware, prevent zero-day exploits, and harden their environments from the inside out. Designed for simplicity, scalability, and speed, ThreatLocker security stack reduces complexity, accelerates compliance, and empowers businesses to take control of their cybersecurity—before threats strike. Headquartered in the United States with a growing global presence, ThreatLocker protects 50,000+ organizations across industries. Learn more here. Media Contact: Stefany Strong [email protected]
Business Upturn
6 hours ago
- Business Upturn
TRYVIO nominated for the 2025 Prix Galien USA 'Best Pharmaceutical Product'
Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of 'Best Pharmaceutical Product' in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025. To qualify for the Prix Galien Award, each candidate must be US Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Advertisement TRYVIO, the first systemic hypertension treatment to target a new pathway in over 30 years, is a dual endothelin receptor antagonist (ERA) indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Martine Clozel, MD, Chief Scientific Officer and Head of Research atf Idorsia, commented: 'We are very proud to have been nominated for this prestigious award. TRYVIO is unique in many aspects. It is the result of many years of work on the endothelin pathway and represents a true therapeutic breakthrough with impressive clinical data. TRYVIO's blood pressure lowering effect was consistent in all studied subgroups of patients, and notably those whose hypertension is notoriously difficult to treat, such as African Americans, elderly patients, and patients with obesity or diabetes. These patients sometimes remain hypertensive despite two, three, or more anti-hypertensive therapies. Plus, TRYVIO provides significant blood pressure lowering for patients with hypertension and chronic kidney disease, a condition affecting millions of patients who are often underserved with the current guideline directed therapies, without risking aggravation of renal function or hyperkalemia.' Despite progress in improving patient outcomes, hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality, affecting an estimated 50% of adults in the US alone, with 50% of those patients not well controlled despite being on medication. These patients face significantly higher risks of cardiovascular events, including heart attack, stroke and kidney failure, and have a markedly increased risk of premature mortality compared to those with controlled blood pressure. Difficult-to-control hypertension is defined as above-goal elevated blood pressure in a patient despite the concurrent use of multiple antihypertensive drug classes. About The Prix Galien Award The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). Notes to the editor About aprocitentan Aprocitentan is Idorsia's once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO™ in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union and the UK and marketing authorization applications are under review in Canada, and Switzerland. About Idorsia The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact: Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 [email protected] – [email protected] – The above information contains certain 'forward-looking statements', relating to the company's business, which can be identified by the use of forward-looking terminology such as 'intend', 'estimates', 'believes', 'expects', 'may', 'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks', 'pending' or 'anticipates' or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
